About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference.

Please note that this position is based in Princeton, NJ or San Diego, CA. Acadia's hybrid model requires this role to work in our office three days per week on average.

Position Summary:

Reporting to the Senior Director, HCP Marketing, the Senior Manager, HCP Marketing – Health Systems & Long-Term Care drives a One Acadia approach to executing Nuplazid’s HCP marketing plan across two priority channels: Health Systems and Long-Term Care (LTC). This role is the dedicated marketing partner to the Health Systems team and the LTC sales organization, translating brand strategy into the value, access, and pull-through resources these field teams need to expand appropriate use of Nuplazid in integrated delivery networks (IDNs), Centers of Excellence (COEs), hospitals, skilled nursing facilities (SNFs), and assisted living facilities (ALFs).

The Senior Manager develops account-based tools, non-personal promotion (NPP), and field materials that support Health System Managers (HSMs) and LTC Sales Specialists & Regional Account Managers (RAMs). Success requires close cross-functional collaboration with Sales, Medical Affairs, Market Access, Patient Services, Analytics, and agency partners, and a disciplined focus on commercial excellence and compliance.

Key Responsibilities:

Health Systems Marketing

Serve as the primary marketing partner to the Health Systems team, developing account-based resources that help HSMs engage IDNs, COEs, hospitals, and key institutions to improve access and appropriate use of Nuplazid.
Build value and access materials anchored in RWE, HEOR, and HCRU data to support the health-system value story and address barriers to adoption.
Collaborate with the Health Information and Technology team to develop tools that support EHR interventions, medication transitions-of-care, and discharge order-set discussions within Centers of Excellence and IDNs, in partnership with Health Systems, Medical, and Compliance.
Create account-planning resources that help the field prioritize accounts and advance systematic opportunities.
Coordinate congress- and KOL-related engagement materials relevant to health systems, in partnership with the Associate Director, Brand Development & KOL Engagement.

Long-Term Care Marketing (supporting the LTC sales team)

Act as the dedicated marketing partner to the LTC sales team, delivering the promotional materials and field tools required to drive appropriate Nuplazid use across SNF and ALF settings.
Own development and maintenance of LTC-specific core visual aids (CVAs), reprints, leave-behinds, and derivative field materials tailored to LTC prescribers
Develop LTC in-service decks, account-planning resources, and facility-directed tools that support engagement with Medical Directors, Directors of Nursing (DONs), consultant pharmacists, and administrators.
Partner with the LTC Regional Account Managers on value/access materials (HCRU-based)
Support LTC Marketing/Insights Committee (MIC) meetings for the channel.
Ensure LTC messaging reflects the unique dynamics of the setting and remains aligned to the overall Nuplazid core story.

Non-Personal Promotion, CRM & Omnichannel

Lead development and execution of CRM and NPP materials — email campaigns, rep-triggered emails (RTEs), digital and banner assets — tailored to Health Systems and LTC customer segments.
Support HCP-facing website content and updates relevant to these channels, ensuring accuracy, compliance, and alignment with omnichannel campaigns.

Cross-Functional Leadership & Execution

Partner across Sales leadership (Health Systems and LTC), Medical Affairs, Market Access, Patient Support Services, Commercial Insights/Analytics (CIP/COBO), Legal, Regulatory, and Compliance to ensure seamless, integrated execution.
Manage agency and vendor partners, including timelines, deliverables, creative quality, and budget tracking for assigned workstreams.
Provide support for national and regional sales meetings, including content development, field training materials, and ongoing training support as needed.
Define metrics for program success, monitor performance, and recommend optimizations.

Compliance & Governance

Ensure all materials and programs adhere to the Medical, Legal, and Regulatory (MLR) review process, legal guidance, corporate policies, and applicable U.S. healthcare laws and regulations.
Model Acadia’s values and a culture of integrity, quality, and cross-functional accountability.

Education & Experience:

Bachelor’s degree in marketing, health care, life sciences, business administration, or a related field; MBA or advanced degree a plus.
A minimum of 8 years of progressively responsible experience in pharmaceutical or biotech marketing (Senior Manager level); 5+ years may be considered at the Manager level.
Prior HCP marketing experience is required (e.g., promotional/NPP materials, CRM, field tools, congress support).
Experience supporting Health Systems / account-based marketing (IDNs, COEs, hospitals) and/or Long-Term Care (SNF/ALF) channels strongly preferred.

Key Skills:

Demonstrated ability to translate RWE, HEOR, and HCRU data into compelling value and access materials.
Demonstrated knowledge of brand management, field execution, and healthcare marketing metrics.
Proven ability to manage agencies and multiple priorities in a dynamic, fast-paced, team-oriented environment.
Strong cross-functional collaboration, communication, and influencing skills; solid understanding of the MLR/promotional review process.
Launch and new-product commercialization experience preferred.
Knowledge of neurology/neuropsychiatry therapeutics and the Neurology, Psychiatry, PCP, and LTC HCP market preferred.

#LI-SM1 #LI-HYBRID

In addition to a competitive base salary, this position is also eligible for discretionary bonus and equity awards based on factors such as individual and organizational performance. Actual amounts will vary depending on experience, performance, and location.

Salary Range

$142,600—$178,300 USD

What we offer US-based Employees:

Competitive base, bonus, new hire and ongoing equity packages
Medical, dental, and vision insurance
Employer-paid life, disability, business travel and EAP coverage
401(k) Plan with a fully vested company match 1:1 up to 5%
Employee Stock Purchase Plan with a 2-year purchase price lock-in
15+ vacation days
13 -15 paid holidays, including office closure between December 24th and January 1st
10 days of paid sick time
Paid parental leave benefit
Tuition assistance

EEO Statement (US-based Employees): Studies have shown that women and people of color are less likely to apply for jobs unless they believe they meet every one of the qualifications in the exact way they are described in job postings. We are committed to building a diverse, equitable, inclusive, and innovative company, and we are looking for the BEST candidate for the job. That candidate may be one who comes from a less traditional background or may meet the qualifications in a different way. We strongly encourage you to apply, especially if the reason you are the best candidate isn’t exactly what we describe here.

It is the policy of Acadia to provide equal employment opportunities to all employees and employment applicants without regard to considerations of race, including related to hairstyle, color, religion or religious creed, sexual orientation, gender, gender identity, gender expression, gender transition, country of origin, ancestry, citizenship, age, physical or mental disability, genetic information, legally-protected medical condition or information, marital status, domestic partner status, family care status, military caregiver status, veteran or military status (including reserve status, National Guard status, and military service or obligation), status as a victim of domestic violence, sexual assault or stalking, enrollment in a public assistance program, or any basis protected under federal, state or local law.

As an equal opportunity employer, Acadia is committed to a diverse workforce. If you are a qualified individual with a disability or a disabled veteran, you have the right to request a reasonable accommodation. Furthermore, you may request additional support if you are unable or limited in your ability to use or access Acadia’s career website due to your disability, along with any accommodations throughout the interview process. To request or inquire about your reasonable accommodation, please complete our Reasonable Accommodation Request Form or contact us at [email protected] or 858-261-2923.

Please note that reasonable accommodations granted throughout the recruiting process are not guaranteed to be the same accommodations given if hired. A new request will need to be submitted for any ADA accommodations after starting employment.

California Applicants: Please see Additional Information for California Residents within our Privacy Policy.

Canadian Applicants: Please see Additional Information for Canadian Residents within our Privacy Policy.

Applicants in the European Economic Area, Switzerland, the United Kingdom, and Serbia: Please see Additional Information for Individuals in the European Economic Area, Switzerland, the United Kingdom, and Serbia within our Privacy Policy.

Notice to Search Firms/Third-Party Recruitment Agencies (Recruiters): The Talent Acquisition team manages the recruitment and employment process for Acadia Pharmaceuticals Inc. (“Acadia”). Acadia does not accept resumes from recruiters or search firms without an executed search agreement in place. Resumes sent to Acadia employees in the absence of an executed search agreement will not obligate Acadia in any way with respect to the future employment of those individuals or potential remuneration to any recruiter or search firm. Candidates should never be submitted directly to our hiring managers or employees.

Salary Range 142600 - 178300 USD

About the company

ACADIA Pharmaceuticals develops and commercializes medicines for central nervous system (CNS) disorders, focusing on neurological and psychiatric conditions with unmet medical needs. Its work centers on identifying drug candidates, advancing them through preclinical and clinical trials, and, upon regulatory approval, bringing therapies to market. Its products address CNS conditions such as Parkinson's disease psychosis, reflecting a commitment to treating complex brain disorders. The company combines in-house research with potential strategic collaborations to expand its portfolio and reach. Unlike peers that rely on a single development path, ACADIA emphasizes a broad pipeline and the ability to commercialize approved therapies, aiming to provide effective CNS treatments to patients and improve outcomes in mental health and neuroscience.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1993

Get referred to Acadia Pharmaceuticals

See people who can refer or advise you

Simplify's Take

What believers are saying

August 4, 2026 revenue guidance rose to $1.24-$1.30 billion.
DAYBUE sales hit $125 million in Q2 2026, up 30% year over year.
FDA Fast Track and September 2026 Phase 2 topline keep remlifanserin catalyst-rich.

What critics are saying

September 24, 2026 remlifanserin missed its Alzheimer psychosis primary endpoint, cutting shares 12.8%.
City of Birmingham v. Acadia securities trial now advances after summary-judgment defeat.
DAYBUE depends on Rett uptake; a 2026 Europe launch must offset any U.S. slowdown.

What makes Acadia Pharmaceuticals unique

Acadia owns DAYBUE and NUPLAZID, the only commercial CNS franchises in its portfolio.
September 2026 Princeton headquarters anchors East Coast operations and conference capacity.
Fast Track remlifanserin and two Phase 2 psychosis programs deepen pipeline optionality.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Holidays
Paid Sick Leave
Paid Parental Leave
Tuition Reimbursement

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

IMA Network

Sep 25th, 2026

Ware Malcomb announces construction is complete on Acadia Pharmaceuticals' Princeton office location.

Ware Malcomb announces construction is complete on Acadia Pharmaceuticals' Princeton office location. PRINCETON, N.J. (September 24, 2026) - Ware Malcomb, an award-winning international design firm, announced construction is complete on a new U.S. East Coast headquarters for Acadia Pharmaceuticals Inc., located at 210 Carnegie Center in Princeton. Ware Malcomb's Princeton office provided interior architecture and design services for the two-level 62,600 SF office and biopharma workplace project. With a presence in Canada and Europe and headquartered in the U.S., Acadia Pharmaceuticals is developing and advancing treatments for neurological disorders and rare diseases, including Parkinson's disease psychosis and Rett syndrome. "We took inspiration from Acadia's brand identity and workplace design principals while tailoring the space to the layout, functionality, and character of the Princeton location. With sustainability in mind, we developed a plan that complements the space and allows the client's brand to be expressed through materials and colors," said Chelsea Chamra, Studio Manager, Interior Architecture & Design, Ware Malcomb. The space encompasses two levels of a five-story building, and the Ware Malcomb team designed an architectural connecting stair as a focal element directly off the reception area, creating a strong connection between the two floors. Through its space planning effort, the design team worked closely with the client to define a new hub and rethink how the workplace supports meetings and interactions with outside vendors and consultants. The first floor is designed to support the day-to-day workplace, incorporating executive offices, smaller meeting rooms, open work areas, a breakroom, and access to an exterior patio. The upper level takes on a more outward-facing role, functioning as a dedicated conference and training center with larger meeting spaces designed to accommodate visitors and group gatherings. The interior design draws from the natural character of the Princeton setting, incorporating biophilic principles through natural materials, daylight, and a connection to the surrounding landscape. A restrained, contemporary palette is balanced with warm textures and exposed architectural elements, creating an environment that feels sophisticated yet approachable. Linear ceiling baffles help define the spaces and create continuity across the broader floor plan, while a combination of exposed concrete, wood flooring, and natural finishes adds depth and variety throughout the interiors. The result is a cohesive workplace that reflects its setting while supporting both focused work and meaningful interaction. Color-changing lighting is incorporated throughout, a feature that allows the company to convey specific color themes correlated with announcements of new medicines or products being introduced into the market, as well as for holidays. Construction services were provided by Structure Tone. Photography credit: Cerrone Photo Established in 1972, Ware Malcomb is a dynamic, forward-thinking commercial real estate design firm providing professional architecture, interior design, civil engineering, branding, building measurement, structural engineering and MEP engineering services to clients throughout the world. With office locations throughout the United States, Canada, Mexico and Brazil, the firm specializes in the design of office, industrial, science & technology, healthcare, multifamily, retail, hospitality and public/institutional projects. The firm is also ranked among the top 10 Architecture/Engineering firms in Engineering News-Record's Top 500 Design Firms and the Top 30 Interior Design Firms in Interior Design magazine's Top 100 Giants. More than half of Fortune 500 companies are Ware Malcomb clients. For more information, visit waremalcomb.com. September 25, 2026 September 23, 2026 September 3, 2026 August 28, 2026 August 26, 2026

ROI-NJ

Sep 25th, 2026

Ware Malcomb says construction finished on Acadia Pharmaceuticals' Princeton office.

Ware Malcomb says construction finished on Acadia Pharmaceuticals' Princeton office. ROI-NJ Staff(Princeton) September 25, 2026 Design firm Ware Malcomb announced that construction is complete on the East Coast headquarters for Acadia Pharmaceuticals Inc., located at 210 Carnegie Center in Princeton. Ware Malcomb's Princeton office provided interior architecture and design services for the two-level 62,600-square-foot office and biopharma workplace project. Acadia Pharmaceuticals is developing and advancing treatments for neurological disorders and rare diseases, including Parkinson's disease psychosis and Rett syndrome. "We took inspiration from Acadia's brand identity and workplace design principals while tailoring the space to the layout, functionality, and character of the Princeton location. With sustainability in mind, we developed a plan that complements the space and allows the client's brand to be expressed through materials and colors," said Chelsea Chamra, studio manager, interior architecture and design, Ware Malcomb. The firm has a presence in Canada and Europe and is based in the U.S. The space spans two levels of a five-story building, and the Ware Malcomb team designed a connecting stair as a focal element directly off the reception area. Through its space planning effort, the design team worked closely with the client to define a new hub and rethink how the workplace supports meetings and interactions with outside vendors and consultants. The first floor supports day-to-day work, with executive offices, smaller meeting rooms, open work areas, a breakroom, and access to an exterior patio. The upper level functions as a dedicated conference and training center with larger meeting spaces designed to accommodate visitors and group gatherings. The interior design draws from the natural character of the Princeton setting, incorporating biophilic principles through natural materials, daylight, and a connection to the surrounding landscape. Acadia Pharmaceuticals is developing and commercializing treatments for rare and neurological disorders, with a focus on both regulatory achievements and clinical advancements.

Insider Monkey

Sep 25th, 2026

ACADIA Pharmaceuticals (ACAD) gets 'sell' rating on weak trial results, shares fall 13%.

ACADIA Pharmaceuticals (ACAD) gets 'sell' rating on weak trial results, shares fall 13%. Published September 24, 2026 at 11:26 pm EDT ACADIA Pharmaceuticals (NASDAQ:ACAD) fell for a fifth consecutive day on Thursday, shedding 12.78 percent to close at $22.18 apiece, after earning a sell recommendation from Goldman Sachs. In its market note, the investment firm reiterated its sell recommendation and $17 price target on the stock after missing its primary endpoint in its phase 2 study of 5-HT2A inverse agonist remlifanserin for the treatment of hallucinations and delusions in patients with Alzheimer's disease psychosis. The price target marked a 23 percent discount from its latest closing price. The clinical study will still progress to its third phase, but the company will be inclined to remove the 30 mg dosage arm due to the lack of improvement in its efficacy during the recently concluded trial. ACADIA Pharmaceuticals said that it plans to present detailed safety and efficacy results from the Phase 2 study in an oral presentation at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston on November 16 to 19, 2026. Additionally, remlifanserin is currently being investigated in an additional Phase 2 study to evaluate its efficacy, safety, and tolerability for the treatment of Lewy body dementia psychosis. Citi, BMO Capital maintain positive ratings. In contrast, Citigroup maintained its buy recommendation on the stock, albeit it lowered its price target to $33 from $40 previously. The reduction was also triggered by the missed primary endpoint. For its part, BMO Capital slashed its price target for the firm to $34 while maintaining an outperform rating, also amid expectations for the drug candidate's reduced probability of success to just 35 percent from 40 percent prior. BMO Capital noted that the phase 2 study trial miss represents a near-term headwind for ACADIA Pharmaceuticals, although it noted that clear response, consistency of SAPS-H+D improvements over time, and stronger efficacy in higher psychosis burden patients all suggest that the treatment candidate is therapeutically active in Alzheimer's disease psychosis. The firm said remlifanserin retains potential to show success in both Alzheimer's disease psychosis and Lewy body dementia psychosis. Strong hedge fund conviction. In terms of institutional sentiment, ACADIA Pharmaceuticals earned a strong backing from hedge fund holders, as evidenced by the jump in their committed capital, even as one fund exited its position. Data from Insider Monkey showed that 38 hedge funds held positions in the stock in the second quarter of the year, down from 39 in the quarter previously. However, the existing investors' combined holdings increased by 13.67 percent to $1.58 billion from $1.39 billion quarter-on-quarter. As the data predate phase 2 trial results, updated hedge fund holdings in the third quarter of the year will offer critical insight on whether the high-conviction buying trend persisted.

Grafa

Sep 24th, 2026

Acadia advances remlifanserin program after Phase 2 Alzheimer's trial results

Daily Dispatch

Aug 25th, 2026

Neuren secures European approval for Rett syndrome treatment.

Neuren secures European approval for Rett syndrome treatment. Neuren Pharmaceuticals has reached a major milestone in the global commercialisation of trofinetide after the European Commission granted marketing authorisation for DAYBU to treat neurobehavioural symptoms associated with Rett syndrome. The approval makes DAYBU the first and only authorised treatment for Rett syndrome in the European Union, extending access to patients aged five years and older across all 27 EU member states as well as Iceland, Liechtenstein and Norway. For the Melbourne-based biotechnology company, the decision represents both an important advance for families affected by the rare neurological disorder and a potentially material commercial catalyst under its licensing arrangement with Acadia Pharmaceuticals. Acadia, which holds Neuren's exclusive worldwide licence to develop and commercialise trofinetide, has previously indicated that it expects to launch DAYBU in Germany in early in the fourth quarter of 2026. Neuren chief executive Jon Pilcher said the approval was especially meaningful given the absence of an approved Rett syndrome treatment in Europe until now. "We are delighted for the Rett syndrome community in Europe, who, until now, have had no approved treatment for this devastating condition," Pilcher said. "The European Commission's approval of DAYBU is particularly rewarding for Neuren given our long-standing commitment to developing therapies for serious neurological disorders with profound unmet need." Rett syndrome is a severe genetic neurodevelopmental condition that predominantly affects girls and can lead to profound impairments in communication, motor function and everyday functioning. The European approval allows DAYBU to be marketed for the treatment of its neurobehavioural symptoms, creating a new treatment option for patients and families across the region. The decision also brings financial significance for Neuren. Under its European licence agreement with Acadia, Neuren is entitled to receive US$35 million following the first commercial sale of DAYBU in Europe. It could also receive up to US$170 million in sales milestone payments as annual net sales reach escalating thresholds, alongside tiered royalties ranging from the mid-teens to the low 20 per cent range. DAYBUE oral solution is already approved for Rett syndrome in the United States, Canada and Israel, while DAYBUE STIX powder has been approved by the US Food and Drug Administration. Trofinetide is not approved for sale in Australia. The European authorisation comes as Neuren continues to advance its broader pipeline of therapies for serious neurological disorders. Its investigational candidate NNZ-2591, also known as ercanetide, is in clinical development for several rare neurodevelopmental conditions, including Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Neuren is also developing NNZ-2591 for hypoxic ischaemic encephalopathy, a form of brain injury that can occur before or shortly after birth. The company is currently running its Phase 3 Koala trial, a randomised, double blind and placebo-controlled study assessing NNZ-2591 in children aged three to 12 years with Phelan-McDermid syndrome, alongside a 52-week open-label extension study.

Acadia Pharmaceuticals

Senior Manager - HCP Marketing, Health Systems & Long-Term Care

About the job

Please note that this position is based in Princeton, NJ or San Diego, CA. Acadia's hybrid model requires this role to work in our office three days per week on average.

About the company

Get referred to Acadia Pharmaceuticals

Simplify's Take

What believers are saying

What critics are saying

What makes Acadia Pharmaceuticals unique

Benefits

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth